Nothing Special   »   [go: up one dir, main page]

EP0804550A4 - Die ex vivo aktivierung von immunzellen - Google Patents

Die ex vivo aktivierung von immunzellen

Info

Publication number
EP0804550A4
EP0804550A4 EP95906781A EP95906781A EP0804550A4 EP 0804550 A4 EP0804550 A4 EP 0804550A4 EP 95906781 A EP95906781 A EP 95906781A EP 95906781 A EP95906781 A EP 95906781A EP 0804550 A4 EP0804550 A4 EP 0804550A4
Authority
EP
European Patent Office
Prior art keywords
immune cells
vivo activation
vivo
activation
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95906781A
Other languages
English (en)
French (fr)
Other versions
EP0804550A1 (de
Inventor
Bruce P Babbitt
Zhengyi J Zhang
Michael E Osband
Joseph James Goodman
Barry Inn Caplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellcor Inc
Original Assignee
Cellcor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/214,400 external-priority patent/US5569585A/en
Application filed by Cellcor Inc filed Critical Cellcor Inc
Publication of EP0804550A1 publication Critical patent/EP0804550A1/de
Publication of EP0804550A4 publication Critical patent/EP0804550A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP95906781A 1994-01-27 1995-01-06 Die ex vivo aktivierung von immunzellen Withdrawn EP0804550A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18826294A 1994-01-27 1994-01-27
US188262 1994-01-27
US214400 1994-03-16
US08/214,400 US5569585A (en) 1993-03-12 1994-03-16 In vitro assay measuring degree of activation of immune cells
US30098294A 1994-09-06 1994-09-06
US300982 1994-09-06
PCT/US1995/000193 WO1995020649A1 (en) 1994-01-27 1995-01-06 Ex vivo activation of immune cells

Publications (2)

Publication Number Publication Date
EP0804550A1 EP0804550A1 (de) 1997-11-05
EP0804550A4 true EP0804550A4 (de) 1998-08-05

Family

ID=27392383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95906781A Withdrawn EP0804550A4 (de) 1994-01-27 1995-01-06 Die ex vivo aktivierung von immunzellen

Country Status (3)

Country Link
EP (1) EP0804550A4 (de)
AU (1) AU1524095A (de)
WO (1) WO1995020649A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696092B2 (en) 1992-02-07 2004-02-24 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
CA2194485C (en) * 1995-05-05 2001-09-18 Anthony Ernest Bolton Endothelial lining effects and treatment of vasospastic disorders
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
DE19814701A1 (de) * 1998-04-01 1999-10-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von mit dem Gehirn assoziierten Erkrankungen, Störungen und Schädigungen
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
DE10120505A1 (de) * 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
US7332158B2 (en) 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
CN115537401B (zh) * 2022-11-09 2025-06-03 杭州百凌生物科技有限公司 一种移植瘤组织的制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017567A1 (en) * 1991-04-05 1992-10-15 Regents Of The University Of Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
WO1993000918A1 (en) * 1991-07-10 1993-01-21 Ochoa Augusto C Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017567A1 (en) * 1991-04-05 1992-10-15 Regents Of The University Of Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
WO1993000918A1 (en) * 1991-07-10 1993-01-21 Ochoa Augusto C Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOLD J E ET AL: "Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: Effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 73 (1). 1994. 115-122, XP002066053 *
GOLD J E ET AL: "Autolymphocyte therapy: II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 71 (3). 1994. 325-332, XP002066054 *
ROSS S.D. ET AL.: "Autolymphocytes therapy (ALT) for disseminated melanoma: results in a pilot study of 26 patients", PROC ANN MEET AM SOC CLIN ONCOL, vol. 12, March 1993 (1993-03-01), pages a1326, XP002066052 *
See also references of WO9520649A1 *

Also Published As

Publication number Publication date
WO1995020649A1 (en) 1995-08-03
AU1524095A (en) 1995-08-15
EP0804550A1 (de) 1997-11-05

Similar Documents

Publication Publication Date Title
TR199501568A2 (tr) Tasikinin öncüleri.
FI970026A7 (fi) Nisäkästelomeraasi
KR970000455A (ko) 배력장치
DE69511410D1 (de) Bleichaktivierung
DE69630610D1 (de) Stimulierung der haarfollikel
DE69519372D1 (de) Hautreinigungsmittel
DE69532166D1 (de) Mikrokatheter
KR960009367A (ko) 인버터장치
DE69115188D1 (de) Leistungswandler.
FI952070A0 (fi) Viskosimetri
DE69709613D1 (de) Schminkdose
EP0804550A4 (de) Die ex vivo aktivierung von immunzellen
DE69502704D1 (de) Hautreinigungsmittel
FI970090L (fi) Suora muuttaja
BR9107022A (pt) Conversor de pressao
DE69111091D1 (de) Kraftverstärker.
FI942858A0 (fi) Ram
FI942320A0 (fi) Hydrokopteri
NO952847D0 (no) Omformer
KR960007758A (ko) 고형비누
FI946068A7 (fi) Leimasimen leimausosa
KR960000216U (ko) 제품의 조립구조
KR960019736U (ko) 구두바닥의 구조
KR950031914U (ko) 브래지어
FR2758470B1 (fr) Le porteur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960827

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 19980619

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE ES FR GB IT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990803